- Home
- CNTB vs STTK Comparison
CNTB vs STTK Comparison
Compare CNTB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- STTK
- Stock Information
- Founded
- CNTB 2012
- STTK 2016
- Country
- CNTB United States
- STTK United States
- Employees
- CNTB N/A
- STTK N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- STTK Health Care
- Exchange
- CNTB Nasdaq
- STTK Nasdaq
- Market Cap
- CNTB 65.5M
- STTK 59.7M
- IPO Year
- CNTB 2021
- STTK 2020
- Fundamental
- Price
- CNTB $1.11
- STTK $1.24
- Analyst Decision
- CNTB Strong Buy
- STTK Hold
- Analyst Count
- CNTB 1
- STTK 3
- Target Price
- CNTB $8.00
- STTK $2.00
- AVG Volume (30 Days)
- CNTB 28.8K
- STTK 357.1K
- Earning Date
- CNTB 09-05-2024
- STTK 11-14-2024
- Dividend Yield
- CNTB N/A
- STTK N/A
- EPS Growth
- CNTB N/A
- STTK N/A
- EPS
- CNTB N/A
- STTK N/A
- Revenue
- CNTB $24,116,000.00
- STTK $6,435,000.00
- Revenue This Year
- CNTB N/A
- STTK $115.09
- Revenue Next Year
- CNTB $63.90
- STTK N/A
- P/E Ratio
- CNTB N/A
- STTK N/A
- Revenue Growth
- CNTB N/A
- STTK 382.75
- 52 Week Low
- CNTB $0.68
- STTK $1.07
- 52 Week High
- CNTB $2.84
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- CNTB 45.31
- STTK 38.29
- Support Level
- CNTB $0.98
- STTK $1.14
- Resistance Level
- CNTB $1.09
- STTK $1.56
- Average True Range (ATR)
- CNTB 0.10
- STTK 0.12
- MACD
- CNTB -0.01
- STTK 0.07
- Stochastic Oscillator
- CNTB 31.28
- STTK 24.42
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.